Advanced

Burden of metastatic bone disease from genitourinary malignancies

Mulders, Peter F.; Abrahamsson, Per-Anders LU and Bukowski, Ronald M. (2010) In Expert Review of Anticancer Therapy 10(11). p.1721-1733
Abstract
Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range... (More)
Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors including prostate renal and bladder cancers and is recommended for preserving bone health (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
targeted therapy, related events, skeletal, genitourinary cancer, bisphosphonates, bone metastases
in
Expert Review of Anticancer Therapy
volume
10
issue
11
pages
1721 - 1733
publisher
Future Drugs Ltd
external identifiers
  • wos:000284495900012
  • scopus:78649284751
ISSN
1744-8328
DOI
10.1586/ERA.10.136
language
English
LU publication?
yes
id
2dbb2333-6d26-4f28-9f2d-e863cc07403f (old id 1752479)
date added to LUP
2011-01-04 07:34:48
date last changed
2018-05-29 09:32:37
@article{2dbb2333-6d26-4f28-9f2d-e863cc07403f,
  abstract     = {Bone metastases are common among patients with stage IV genitourinary cancers Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event These events are associated with increased medical expenses and decreased quality of life Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors including prostate renal and bladder cancers and is recommended for preserving bone health},
  author       = {Mulders, Peter F. and Abrahamsson, Per-Anders and Bukowski, Ronald M.},
  issn         = {1744-8328},
  keyword      = {targeted therapy,related events,skeletal,genitourinary cancer,bisphosphonates,bone metastases},
  language     = {eng},
  number       = {11},
  pages        = {1721--1733},
  publisher    = {Future Drugs Ltd},
  series       = {Expert Review of Anticancer Therapy},
  title        = {Burden of metastatic bone disease from genitourinary malignancies},
  url          = {http://dx.doi.org/10.1586/ERA.10.136},
  volume       = {10},
  year         = {2010},
}